WebDoctor Encyclopedia

Breast Childhood Invasive carcinoma Special types

Secretory carcinoma of the breast

Secretory carcinoma is a rare, slow-growing special type of breast cancer that can affect children, adults and men. Most carry the ETV6::NTRK3 fusion. Surgery is the main treatment and the outlook is generally excellent.

Medically reviewed Last reviewed October 21, 2026

What is secretory carcinoma of the breast?

Secretory carcinoma of the breast is a rare, usually slow-growing type of breast cancer. Its name comes from the milky, bubbly material, called secretions, that the tumour cells produce and store inside and around them. It makes up well under 1% of all breast cancers.

It was first described in children, and it was once called juvenile breast carcinoma. It is still the most common type of breast cancer in children and teenagers. However, most people with this cancer are adults, with a median age in the late 40s to mid-50s (Gong et al., 2021; Boustros et al., 2024). It can also affect men.

Most of these tumours carry a specific gene fusion called ETV6::NTRK3. This fusion drives the growth of the cancer and can be targeted with modern tablets called TRK inhibitors if the disease spreads (Mortensen et al., 2021).

How it differs from secretory carcinoma of the salivary gland

A tumour with the same appearance and the same ETV6::NTRK3 fusion also occurs in the salivary glands, described on our page on secretory carcinoma of the salivary gland. The salivary tumour was once called “mammary analogue secretory carcinoma” because it looks so much like the breast version.

Feature Secretory carcinoma of the breast Secretory carcinoma of the salivary gland
Site Breast Parotid and other salivary glands
Main treatment Breast surgery, with radiotherapy for most adults Removal of the salivary gland
Lymph nodes Armpit nodes Neck nodes
Related care Managed by a breast team Managed by a head and neck team
Shared feature ETV6::NTRK3 fusion ETV6::NTRK3 fusion

1. Key facts at a glance

Feature Details
Type of cancer Rare special type of invasive breast cancer
How common Well under 1% of breast cancers
Typical age Any age from early childhood to old age; median about 48-56 years
Sex Mostly women; men and children also affected
Gene change ETV6::NTRK3 fusion in most cases
Hormone receptors Variable; many are triple-negative or only weakly positive
Main treatment Surgery, usually with radiotherapy in adults
Targeted treatment TRK inhibitors such as larotrectinib and entrectinib for advanced disease
Outlook Generally excellent

2. Types

By age group

Group Features
Children and teenagers Most common breast cancer type in this age group; usually small and very slow-growing
Adults Most cases; outlook still good, but slightly more risk with older age
Men Occasional cases; treated in the same way

By behaviour

Type Description
Classic (low-grade) Mild nuclear changes, few dividing cells
High-grade or dedifferentiated Rare cases with more aggressive features

3. Causes and risk factors

The cause is not known. The ETV6::NTRK3 fusion arises by chance in the tumour cells and is not inherited.

Factor Notes
ETV6::NTRK3 fusion Found in the tumour cells of most cases
Age Can occur at any age
Sex Mainly women
Family history No clear link
BRCA1 or BRCA2 Not specifically linked
Hormones No proven link

What does the fusion do?

The fusion joins part of the ETV6 gene to part of the NTRK3 gene. The resulting protein keeps a growth signal called TRK switched on all the time, which pushes cells to survive and multiply (Mortensen et al., 2021). The same fusion is found in a few other cancers, including secretory carcinoma of the salivary gland and infantile fibrosarcoma.

Why is it so slow-growing?

Most breast cancers develop through a gradual build-up of many genetic changes. Secretory carcinoma is different: a single fusion gene seems to be enough to start the tumour, and the cancer cells often have few other genetic faults. This simpler genetic make-up may explain why many tumours grow slowly and rarely spread beyond the armpit.

4. How does it look

In the breast

Finding Description
Lump A firm, painless, slowly growing lump
Location Often near the nipple in children and young people
Size Usually small; average about 2 cm in a US series
Skin and nipple Usually normal

On scans

Scan Typical findings
Mammogram A rounded or irregular mass, sometimes with calcification; may look harmless
Ultrasound A well-defined or slightly irregular mass
MRI Used if the extent is unclear

Imaging findings are not specific, and some tumours look like benign lumps (Boustros et al., 2024). A biopsy is therefore needed for any new solid lump.

Under the microscope

Feature Description
Secretions Pink, bubbly material inside cells and in spaces between them
Growth pattern Small cysts, solid areas and tube-like structures
Nuclei Mild to moderate changes
Dividing cells Few
Stains S100, mammaglobin, SOX10 and pan-TRK often positive
Molecular test ETV6::NTRK3 fusion by FISH or sequencing

5. Symptoms

Common symptoms

  • A painless lump in the breast
  • A lump that grows slowly over months or years
  • In children, a lump beneath or near the nipple

Less common symptoms

Symptom Possible cause
Lump in the armpit Spread to lymph nodes
Nipple discharge Uncommon
Change in breast shape Larger tumours
Cough, breathlessness or abdominal pain Rare distant spread to the lungs or liver

Why diagnosis can be delayed

Because the lump is usually painless and grows slowly, people may watch it for months. In young people, doctors may first think of a harmless fibroadenoma. A biopsy settles the question.

When to seek medical advice

See a doctor about any new breast lump, at any age. In children, most breast lumps are harmless, but a lump that keeps growing should be checked. Men should also report breast lumps.

6. Diagnosis

Step What is done
Examination Breast and armpit
Ultrasound First test in younger patients
Mammogram For adults
Core needle biopsy Provides tissue for diagnosis
Receptor testing ER, PR and HER2 status
Molecular testing Confirms ETV6::NTRK3 fusion
Staging scans Only if the tumour is large or nodes are involved

Staging

Secretory carcinoma is staged with the TNM system for breast cancer.

Stage Simplified meaning
Stage I Small tumour, no or minimal node spread
Stage II Larger tumour or a few armpit nodes
Stage III Large tumour or extensive node spread
Stage IV Distant spread

Most people are diagnosed at an early stage. In a US database of 190 patients, about seven in ten had no lymph node spread (Gong et al., 2021).

7. Treatment

Treatment is planned by a breast cancer team, with input from children’s cancer specialists for young patients.

Surgery

Option Notes
Breast-conserving surgery Removes the tumour with a margin; preferred where possible
Mastectomy For larger tumours or patient choice
Sentinel node biopsy Checks whether the cancer has reached the armpit nodes
Breast-bud preservation In young girls, surgeons try to protect the developing breast

In the US database, people who had breast-conserving surgery with radiotherapy had better breast cancer-specific survival than those who had a mastectomy (Gong et al., 2021).

Radiotherapy

Group Approach
Adults after breast-conserving surgery Usually recommended
Children Usually avoided because of long-term effects on the growing body

A narrative review noted that most experts advise radiotherapy for adults but not for children (Min et al., 2022).

Drug treatments

Treatment Role
Chemotherapy Uncertain benefit for early disease; considered for high-risk or advanced cases
Hormone therapy Considered when the tumour is hormone receptor-positive
TRK inhibitors (larotrectinib, entrectinib) Approved for NTRK fusion-positive solid tumours that have spread or cannot be removed
Clinical trials For rare advanced cases

TRK inhibitors have shown high response rates across many cancers with NTRK fusions, including secretory carcinoma (Mortensen et al., 2021).

Why receptor results can be confusing

Secretory carcinomas are often triple-negative, meaning they lack oestrogen and progesterone receptors and HER2. In common breast cancer, triple-negative tumours tend to be aggressive and usually need chemotherapy. Secretory carcinoma is an exception: despite often being triple-negative, it usually behaves gently.

Doctors therefore base treatment on the tumour type and stage, rather than on receptor status alone. Some secretory carcinomas are hormone receptor-positive, and in the US database more than half of those tested were ER-positive (Gong et al., 2021).

Side effects

Treatment Possible side effects
Surgery Pain, scarring, change in breast shape, arm swelling after node surgery
Radiotherapy Skin redness, tiredness, breast firmness
Hormone therapy Hot flushes, joint aches
TRK inhibitors Dizziness, weight gain, tiredness, raised liver enzymes

8. Outlook (prognosis)

Secretory carcinoma generally has an excellent outlook, better than the common no special type breast cancer (Boustros et al., 2024).

Factor Effect
Age under 20 Associated with a better outlook
Tumour under 2 cm Associated with a better outlook
Three or fewer involved nodes Associated with a better outlook
Older age Linked to lower breast cancer-specific survival in the US database
Distant spread Rare, but more serious when it happens

Late recurrences can happen, sometimes many years after surgery, and a few tumours come back early (Mortensen et al., 2021). Long-term follow-up is therefore advised.

9. Follow-up

Period Typical checks
Years 1-5 Clinical review every 6-12 months; yearly mammogram for adults
After 5 years Yearly review and imaging as advised
Children Follow-up in a children’s or young adult service, often with ultrasound

10. Living with secretory carcinoma of the breast

  • Attend follow-up, as late recurrences are possible
  • Check your breasts and armpits and report changes
  • Do arm exercises after node surgery
  • Keep active and maintain a healthy weight
  • Ask about breast reconstruction if you had a mastectomy
  • Seek support from breast cancer charities and young people’s services

Recovery after surgery

Period What to expect
First days Mild to moderate pain, wound care, drain if node surgery was done
1-2 weeks Return to light activities; arm exercises after node surgery
3-6 weeks Most people return to work and normal routines
If radiotherapy follows Usually starts 4-6 weeks after surgery and lasts 1-3 weeks

For children and families

A breast cancer diagnosis in a child is very rare and can be shocking for families. Children’s cancer centres can provide play specialists, psychologists and family support. Most children do extremely well, and treatment is planned to protect future breast development as much as possible.

Coping with a rare breast cancer

Most information about breast cancer is written for the common types, so some advice you read may not apply to you. Ask your breast care nurse which parts of general guidance are relevant. Many people find it reassuring to learn that this cancer usually has a very good outlook, while still taking follow-up seriously. Breast cancer charities can offer peer support and practical help.

11. Frequently asked questions

Question Answer
Is it only a children’s cancer? No; most patients are adults
Is it inherited? No; the fusion arises only in the tumour
Do I need chemotherapy? Usually not for small, early tumours
What is a TRK inhibitor? A tablet that blocks the signal from the NTRK fusion; used if the cancer spreads
Can men get it? Yes, rarely
Will it affect breastfeeding later? Surgery on one breast may reduce milk from that side, but the other breast usually works normally
Is it the same as the salivary gland tumour? It shares the same fusion and look, but starts in the breast

12. Questions to ask your care team

  • Has the ETV6::NTRK3 fusion been confirmed?
  • What are the hormone receptor and HER2 results?
  • Can I have breast-conserving surgery?
  • Do I need radiotherapy, chemotherapy or hormone therapy?
  • Have my lymph nodes been checked?
  • How long will follow-up last?
  • If the cancer comes back, could I have a TRK inhibitor?
  • Is there a breast care nurse I can contact between appointments?

Resources

  1. Boustros, P. et al. (2024) ‘Secretory carcinoma of the breast: radiologic-pathologic correlation’, Journal of Breast Imaging, 6(5), pp. 520-528.
  2. Gong, P. et al. (2021) ‘Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast’, Scientific Reports, 11(1), 14738.
  3. Min, N. et al. (2022) ‘Advancement of secretory breast carcinoma: a narrative review’, Annals of Translational Medicine, 10(21), 1178.
  4. Mortensen, L. et al. (2021) ‘Locally recurrent secretory carcinoma of the breast with NTRK3 gene fusion’, The Oncologist, 26(10), pp. 818-824.
  5. National Cancer Institute (2026) Breast Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/breast/hp/breast-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.